Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase

NCT02890992 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02890992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02890992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
September 15, 2016
Completion date
February 22, 2019
Enrollment
42 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolaemia